Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
2(33%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
4
67%
Ph phase_2
2
33%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(1)
Terminated(2)
Other(1)

Detailed Status

Withdrawn1
Completed1
Recruiting1
Active, not recruiting1
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 22 (33.3%)

Trials by Status

withdrawn117%
completed117%
recruiting117%
active_not_recruiting117%
terminated117%
unknown117%

Recent Activity

2 active trials
Showing 5 of 6
recruitingphase_1

Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

NCT06432036
terminatedphase_2

Radioembolization in Elderly/ Fragile Patients With mCRC

NCT05092880
active_not_recruitingphase_1

Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer

NCT03028311
completedphase_1

Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC

NCT04124991
withdrawnphase_1

Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery

NCT03117855
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06432036Phase 1

Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

Recruiting
NCT05092880Phase 2

Radioembolization in Elderly/ Fragile Patients With mCRC

Terminated
NCT03028311Phase 1

Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer

Active Not Recruiting
NCT04124991Phase 1

Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC

Completed
NCT03117855Phase 1

Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery

Withdrawn
NCT01898962Phase 2

Definitive Therapy for Oligometastatic Solid Malignancies

Unknown

All 6 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
6